Retinal Vascular Emergencies · Surgeon Series
Sudden. Painless.
One eye. This is
a stroke of the retina.
Central retinal artery occlusion blocks the eye's own blood supply the same way a cerebral stroke blocks the brain's — except it happens in an organ you can look straight into with an ophthalmoscope. The retina tolerates interrupted blood flow for minutes, not hours, and the outcome turns on how fast the blockage is recognised and where the underlying clot actually came from.
tolerance ceiling
as a stroke subtype
treatments for CRAO
Section 01 — The Eye's Own Stroke
Blocked artery.
Starved retina.
The clock starts immediately.
Patients describe it almost identically: vision in one eye simply went, with no pain, no warning, often on waking or mid-conversation. That description is not incidental — it is the signature of an embolic event, the same signature a stroke neurologist would recognise instantly if it happened in a limb or in speech instead of in an eye.
Central retinal artery occlusion (CRAO) is a sudden blockage of the central retinal artery — the vessel, branching from the ophthalmic artery, that supplies blood to the inner layers of the retina. Most cases are embolic: a fragment of material, usually cholesterol plaque from the carotid arteries or a clot from the heart, travels downstream and lodges in a vessel too narrow to pass. The retina has one of the lowest tolerances for interrupted blood flow of any tissue examined, which is why this condition is managed as a genuine emergency even though, honestly, the treatment options available once the blockage has happened are limited.
Central retinal artery occlusion (CRAO) is a sudden blockage of the eye's main blood supply, almost always by an embolus travelling from the carotid arteries or the heart, and it behaves exactly like an ischemic stroke — because that is what it is, just downstream in the eye rather than the brain. Vision loss is typically sudden, painless and profound in the affected eye. Unlike a limb, the retina has almost no tolerance for interrupted blood flow: animal-model data suggests meaningful, irreversible damage begins within roughly 90 minutes, though the exact human threshold is not known with precision. Because the embolic source causing a CRAO is the same one that causes cerebral stroke, current guidance treats every CRAO patient as needing the same urgent vascular work-up as a stroke or TIA, regardless of whether useful vision ever returns.
Section 02 — Interactive
The number that decides
everything: minutes.
Move the clock forward and watch how an ischemic retina is presumed to change at each stage, based on the animal-model tolerance data underlying current emergency guidance. This is a simplified, illustrative model of tissue-level change over time — not a diagnostic tool, and not a precise human timeline, since human retinal tolerance has never been measured this exactly.
Within the first hour or so, the retina is under severe metabolic stress but — in principle — still salvageable if flow is restored; this is the rationale behind bedside measures like ocular massage or anterior chamber paracentesis, though none has been reliably shown in controlled trials to restore flow. Past roughly 90 to 100 minutes, Hayreh's primate experiments found retinal damage became substantial, and by around four hours, close to complete. Human eyes have not been subjected to controlled experiments of this kind, for obvious reasons, and case reports describe partial recovery after longer intervals than the animal data would predict — so the 90-minute figure functions as a conservative biological ceiling used to justify treating CRAO as a true emergency, not as a stopwatch that determines whether treatment is worth attempting.
Section 03 — Why Speed Decides Everything
Same blockage,
different address.
The prognosis moves with it.
Not every retinal artery occlusion behaves the same way. Where exactly the blockage sits — the ophthalmic artery, the central retinal artery trunk, or a single branch — changes both what the eye exam shows and how much vision has a realistic chance of surviving.
The 'cherry red spot' is the single most recognisable sign of CRAO on fundus exam. As the inner retina infarcts, the nerve fibre and ganglion cell layers swell and turn opaque white, most visibly around the macula where those layers are thickest. The fovea itself has almost none of that inner retinal tissue — light reaches the photoreceptors almost directly there — and sits over the still-intact choroidal circulation underneath. Against the surrounding pallor, the thin, choroid-perfused fovea shows through as a comparatively red spot at the centre of a pale retina. It is a contrast artefact of anatomy, not evidence that central vision has been spared.
| Occlusion site | Field defect | Cherry-red spot? | General prognosis |
|---|---|---|---|
| Ophthalmic artery occlusion | Severe, often near-total field loss | Often absent — choroidal supply is also compromised | Generally the worst of the group |
| Central retinal artery occlusion (trunk) | Near-total field loss, aside from any cilioretinal-sparing island | Classically present | Poor without spontaneous reperfusion or a sparing vessel |
| Branch retinal artery occlusion (BRAO) | Sectoral / altitudinal defect matching the branch's territory | Localised pallor only, not a full spot | Generally better — unaffected retina is preserved |
| Transient monocular vision loss (amaurosis fugax) | Curtain-like, fully reversible within minutes | Not applicable — no infarction if truly transient | Vision recovers, but carries the same warning value |
A cilioretinal artery — a small vessel arising directly from the choroidal circulation rather than the central retinal artery — is present in a meaningful minority of eyes and, when it supplies part of the macula, can preserve a central island of vision even through an otherwise complete CRAO. It is one of the few pieces of genuinely good anatomical luck in this condition, and one reason funduscopic findings are examined carefully rather than assumed from the diagnosis alone.
Section 04 — Where the Embolus Comes From
The clot did not
start in the eye.
That is the real emergency.
Treating CRAO as purely an ophthalmic event misses the point. In the large majority of cases, the retinal artery is a downstream casualty of disease sitting somewhere else entirely — the carotid arteries, the heart, or, in a subset of older patients, an inflamed artery wall that has nothing to do with cholesterol at all.
Giant cell arteritis deserves special mention because it is the one cause of CRAO where speed of a different kind matters: speed of steroid treatment, not speed of ophthalmic intervention. Jaw claudication, scalp tenderness, new temporal headache, unexplained weight loss and polymyalgia symptoms in a patient over 50 presenting with sudden vision loss should prompt same-day ESR and CRP testing and, in most protocols, empiric high-dose systemic corticosteroids started before a confirmatory temporal artery biopsy — because waiting for biopsy confirmation risks the fellow eye.
Section 05 — What the Evidence Actually Shows
The eye's stroke,
on the same
guidelines as the brain's.
The clinical literature on CRAO over the past two decades has moved in one consistent direction: away from treating it as a self-contained eye problem, and toward treating it as a cerebrovascular event that happens to present to an ophthalmologist first.
In 2021, the American Heart Association and American Stroke Association issued a scientific statement formally classifying acute retinal ischemia, including CRAO, as a stroke subtype, and recommending the same urgent evaluation pathway used for cerebral TIA and stroke — same-day imaging, carotid and cardiac evaluation, and secondary-prevention treatment, regardless of whether the eye itself ever recovers vision. That recommendation did not appear from nowhere: diffusion-weighted MRI studies in CRAO patients have repeatedly found a meaningful minority with an acute, clinically silent brain infarct elsewhere at the time they present with eye symptoms — vision loss the patient noticed, brain injury they did not.
On the treatment side, the evidence is far less reassuring than patients usually hope. Traditional bedside measures — ocular massage, anterior chamber paracentesis to lower intraocular pressure, breathing a carbon-dioxide-enriched gas mixture to dilate retinal vessels, hyperbaric oxygen — have circulated in the literature for decades without controlled-trial evidence that any of them reliably restores vision, a gap summarised bluntly in a widely cited 2018 editorial urging clinicians to follow evidence-based emergency guidelines rather than reflexive bedside manoeuvres. Intravenous thrombolysis, the definitive treatment for many ischemic cerebral strokes, was tested specifically for CRAO in the European EAGLE trial; the trial did not demonstrate a visual benefit over conservative management sufficient to justify the added bleeding risk, and it remains the strongest controlled evidence against routine thrombolysis for CRAO outside a research protocol. At the time of writing, there is no FDA-approved pharmacologic treatment specific to CRAO.
Illustrative visualisation of the direction and rough weight of the cited literature — see References for source studies. Not pooled meta-analytic effect sizes or precise percentages.
ceiling, animal-model estimate
mandatory GCA rule-out
specific to CRAO
Section 06 — Real Risk, Honestly Stated
Doing nothing,
and doing something,
both carry risk.
It would be dishonest to describe CRAO management as a simple 'try everything, it can't hurt' emergency. Some traditional bedside interventions carry their own risk, thrombolysis carries a real bleeding risk, and the single biggest risk of all is treating this as an eye-only problem and skipping the vascular work-up entirely.
| Risk | Why it matters in CRAO |
|---|---|
| Missed giant cell arteritis | Delayed steroid treatment risks bilateral blindness within days and systemic vascular complications — the single most time-critical diagnosis to exclude |
| Recurrent stroke or heart attack without work-up | The embolic source causing the CRAO remains untreated and can cause a subsequent, potentially disabling cerebral or cardiac event |
| Thrombolysis bleeding risk | IV tPA carries a real intracranial and systemic haemorrhage risk that, per the EAGLE trial, was not clearly offset by visual benefit |
| Anterior chamber paracentesis | An invasive bedside procedure with its own small risk of infection, hyphema or lens injury, for a benefit that remains unproven |
| Neovascular complications | Less common than after an ischemic central retinal vein occlusion, but iris and angle neovascularisation are documented after CRAO and warrant monitoring for months afterward |
| Permanent field loss despite guideline-concordant care | Even prompt, correct management does not reliably restore central vision once infarction has occurred — the retina's poor collateral supply is the fundamental limit, not a failure of treatment |
Section 07 — Where the Decision Actually Gets Made
The eye exam ends.
The stroke
work-up begins.
In a well-run pathway, the ophthalmologist's job is not just to diagnose CRAO on fundus exam — it is to trigger the same urgent referral a neurologist would trigger for a TIA, on the same day, before the patient leaves the building.
That work-up looks functionally identical to a TIA clinic pathway, run in parallel with the ophthalmic assessment rather than instead of it: same-day carotid duplex ultrasound, an electrocardiogram and often extended cardiac monitoring for paroxysmal atrial fibrillation, echocardiography where a cardioembolic source is suspected, same-day ESR and CRP with a low threshold for temporal artery biopsy in patients over 50, and a full lipid and vascular risk-factor review.
A patient in their late sixties wakes up with painless, complete loss of vision in one eye and is seen the same morning. Fundus exam shows retinal whitening and a cherry-red spot consistent with CRAO. No headache, no jaw pain, nothing pointing toward arteritis. What the eye exam cannot show is why the artery blocked — that question sends the patient for carotid duplex imaging the same day, which finds a high-grade stenosis on the side matching the affected eye.
The vision in that eye does not meaningfully recover; by the time of presentation, the ischemic window described in the animal-model data had already closed. But the carotid finding changes the rest of the patient's care — evaluation for endarterectomy or stenting, antiplatelet therapy, risk-factor management — precisely the intervention that reduces the risk of a subsequent, and potentially far more disabling, cerebral stroke. The eye did not save its own vision. It found the disease that could have taken far more.
Section 08 — FAQ
Frequently asked questions
about CRAO.
CRAO is a sudden blockage of the central retinal artery, the vessel that supplies blood to the inner layers of the retina. It typically causes sudden, painless, and often severe loss of vision in one eye, and is usually caused by an embolus — a fragment of clot or cholesterol plaque — travelling from the carotid arteries or the heart.
Functionally, yes. The retina is technically part of the central nervous system, and a CRAO is caused by the same kind of vascular blockage — usually an embolus — that causes an ischemic stroke in the brain. In 2021 the American Heart Association and American Stroke Association formally classified acute retinal ischemia as a stroke subtype and recommended the same urgent vascular work-up used for cerebral stroke or TIA, regardless of whether vision in the eye recovers.
It's the classic fundus exam finding in CRAO. The retina around the macula turns pale as the inner retinal layers infarct and swell, while the very centre of the macula — the fovea, which has almost no inner retinal tissue and sits over the still-intact choroidal blood supply — stays comparatively red by contrast. It's a sign of the pattern of damage, not evidence that central vision has been spared.
Sometimes, but it is unpredictable and often limited. Recovery depends heavily on how quickly blood flow is restored, whether a protective cilioretinal artery happens to spare part of the macula, and how complete the original blockage was. Animal-model data suggests the retina's tolerance for complete ischemia is on the order of 90 minutes to a few hours before damage becomes substantial, which is why CRAO is treated as a true time-critical emergency even though, honestly, no treatment reliably reverses established damage.
The eye exam confirms the diagnosis, but the more important work happens afterward: same-day carotid duplex ultrasound, an ECG and often extended heart-rhythm monitoring, blood tests including ESR and CRP to screen for giant cell arteritis, and a broader cardiovascular risk-factor review. The goal is finding the embolic or inflammatory source before it causes a second, potentially more disabling event — commonly a cerebral stroke.
Giant cell arteritis is an inflammatory disease of medium and large arteries that, in patients typically over 50, can cause an arteritic form of CRAO. It matters because it is treated completely differently from embolic CRAO — with urgent high-dose systemic corticosteroids, often started before a confirmatory temporal artery biopsy — and because an untreated arteritic CRAO carries a real risk of blinding the second eye within days if not recognised.
References & Evidence Base
Peer-reviewed
citations.
Continue Reading
Related guides
from Beyond Vision.
Retinal Vascular Emergencies · Surgeon Series
Sudden. Painless.
One eye. This is
a stroke of the retina.
Central retinal artery occlusion blocks the eye's own blood supply the same way a cerebral stroke blocks the brain's — except it happens in an organ you can look straight into with an ophthalmoscope. The retina tolerates interrupted blood flow for minutes, not hours, and the outcome turns on how fast the blockage is recognised and where the underlying clot actually came from.
tolerance ceiling
as a stroke subtype
treatments for CRAO
Section 01 — The Eye's Own Stroke
Blocked artery.
Starved retina.
The clock starts immediately.
Patients describe it almost identically: vision in one eye simply went, with no pain, no warning, often on waking or mid-conversation. That description is not incidental — it is the signature of an embolic event, the same signature a stroke neurologist would recognise instantly if it happened in a limb or in speech instead of in an eye.
Central retinal artery occlusion (CRAO) is a sudden blockage of the central retinal artery — the vessel, branching from the ophthalmic artery, that supplies blood to the inner layers of the retina. Most cases are embolic: a fragment of material, usually cholesterol plaque from the carotid arteries or a clot from the heart, travels downstream and lodges in a vessel too narrow to pass. The retina has one of the lowest tolerances for interrupted blood flow of any tissue examined, which is why this condition is managed as a genuine emergency even though, honestly, the treatment options available once the blockage has happened are limited.
Central retinal artery occlusion (CRAO) is a sudden blockage of the eye's main blood supply, almost always by an embolus travelling from the carotid arteries or the heart, and it behaves exactly like an ischemic stroke — because that is what it is, just downstream in the eye rather than the brain. Vision loss is typically sudden, painless and profound in the affected eye. Unlike a limb, the retina has almost no tolerance for interrupted blood flow: animal-model data suggests meaningful, irreversible damage begins within roughly 90 minutes, though the exact human threshold is not known with precision. Because the embolic source causing a CRAO is the same one that causes cerebral stroke, current guidance treats every CRAO patient as needing the same urgent vascular work-up as a stroke or TIA, regardless of whether useful vision ever returns.
Section 02 — Interactive
The number that decides
everything: minutes.
Move the clock forward and watch how an ischemic retina is presumed to change at each stage, based on the animal-model tolerance data underlying current emergency guidance. This is a simplified, illustrative model of tissue-level change over time — not a diagnostic tool, and not a precise human timeline, since human retinal tolerance has never been measured this exactly.
Within the first hour or so, the retina is under severe metabolic stress but — in principle — still salvageable if flow is restored; this is the rationale behind bedside measures like ocular massage or anterior chamber paracentesis, though none has been reliably shown in controlled trials to restore flow. Past roughly 90 to 100 minutes, Hayreh's primate experiments found retinal damage became substantial, and by around four hours, close to complete. Human eyes have not been subjected to controlled experiments of this kind, for obvious reasons, and case reports describe partial recovery after longer intervals than the animal data would predict — so the 90-minute figure functions as a conservative biological ceiling used to justify treating CRAO as a true emergency, not as a stopwatch that determines whether treatment is worth attempting.
Section 03 — Why Speed Decides Everything
Same blockage,
different address.
The prognosis moves with it.
Not every retinal artery occlusion behaves the same way. Where exactly the blockage sits — the ophthalmic artery, the central retinal artery trunk, or a single branch — changes both what the eye exam shows and how much vision has a realistic chance of surviving.
The 'cherry red spot' is the single most recognisable sign of CRAO on fundus exam. As the inner retina infarcts, the nerve fibre and ganglion cell layers swell and turn opaque white, most visibly around the macula where those layers are thickest. The fovea itself has almost none of that inner retinal tissue — light reaches the photoreceptors almost directly there — and sits over the still-intact choroidal circulation underneath. Against the surrounding pallor, the thin, choroid-perfused fovea shows through as a comparatively red spot at the centre of a pale retina. It is a contrast artefact of anatomy, not evidence that central vision has been spared.
| Occlusion site | Field defect | Cherry-red spot? | General prognosis |
|---|---|---|---|
| Ophthalmic artery occlusion | Severe, often near-total field loss | Often absent — choroidal supply is also compromised | Generally the worst of the group |
| Central retinal artery occlusion (trunk) | Near-total field loss, aside from any cilioretinal-sparing island | Classically present | Poor without spontaneous reperfusion or a sparing vessel |
| Branch retinal artery occlusion (BRAO) | Sectoral / altitudinal defect matching the branch's territory | Localised pallor only, not a full spot | Generally better — unaffected retina is preserved |
| Transient monocular vision loss (amaurosis fugax) | Curtain-like, fully reversible within minutes | Not applicable — no infarction if truly transient | Vision recovers, but carries the same warning value |
A cilioretinal artery — a small vessel arising directly from the choroidal circulation rather than the central retinal artery — is present in a meaningful minority of eyes and, when it supplies part of the macula, can preserve a central island of vision even through an otherwise complete CRAO. It is one of the few pieces of genuinely good anatomical luck in this condition, and one reason funduscopic findings are examined carefully rather than assumed from the diagnosis alone.
Section 04 — Where the Embolus Comes From
The clot did not
start in the eye.
That is the real emergency.
Treating CRAO as purely an ophthalmic event misses the point. In the large majority of cases, the retinal artery is a downstream casualty of disease sitting somewhere else entirely — the carotid arteries, the heart, or, in a subset of older patients, an inflamed artery wall that has nothing to do with cholesterol at all.
Giant cell arteritis deserves special mention because it is the one cause of CRAO where speed of a different kind matters: speed of steroid treatment, not speed of ophthalmic intervention. Jaw claudication, scalp tenderness, new temporal headache, unexplained weight loss and polymyalgia symptoms in a patient over 50 presenting with sudden vision loss should prompt same-day ESR and CRP testing and, in most protocols, empiric high-dose systemic corticosteroids started before a confirmatory temporal artery biopsy — because waiting for biopsy confirmation risks the fellow eye.
Section 05 — What the Evidence Actually Shows
The eye's stroke,
on the same
guidelines as the brain's.
The clinical literature on CRAO over the past two decades has moved in one consistent direction: away from treating it as a self-contained eye problem, and toward treating it as a cerebrovascular event that happens to present to an ophthalmologist first.
In 2021, the American Heart Association and American Stroke Association issued a scientific statement formally classifying acute retinal ischemia, including CRAO, as a stroke subtype, and recommending the same urgent evaluation pathway used for cerebral TIA and stroke — same-day imaging, carotid and cardiac evaluation, and secondary-prevention treatment, regardless of whether the eye itself ever recovers vision. That recommendation did not appear from nowhere: diffusion-weighted MRI studies in CRAO patients have repeatedly found a meaningful minority with an acute, clinically silent brain infarct elsewhere at the time they present with eye symptoms — vision loss the patient noticed, brain injury they did not.
On the treatment side, the evidence is far less reassuring than patients usually hope. Traditional bedside measures — ocular massage, anterior chamber paracentesis to lower intraocular pressure, breathing a carbon-dioxide-enriched gas mixture to dilate retinal vessels, hyperbaric oxygen — have circulated in the literature for decades without controlled-trial evidence that any of them reliably restores vision, a gap summarised bluntly in a widely cited 2018 editorial urging clinicians to follow evidence-based emergency guidelines rather than reflexive bedside manoeuvres. Intravenous thrombolysis, the definitive treatment for many ischemic cerebral strokes, was tested specifically for CRAO in the European EAGLE trial; the trial did not demonstrate a visual benefit over conservative management sufficient to justify the added bleeding risk, and it remains the strongest controlled evidence against routine thrombolysis for CRAO outside a research protocol. At the time of writing, there is no FDA-approved pharmacologic treatment specific to CRAO.
Illustrative visualisation of the direction and rough weight of the cited literature — see References for source studies. Not pooled meta-analytic effect sizes or precise percentages.
ceiling, animal-model estimate
mandatory GCA rule-out
specific to CRAO
Section 06 — Real Risk, Honestly Stated
Doing nothing,
and doing something,
both carry risk.
It would be dishonest to describe CRAO management as a simple 'try everything, it can't hurt' emergency. Some traditional bedside interventions carry their own risk, thrombolysis carries a real bleeding risk, and the single biggest risk of all is treating this as an eye-only problem and skipping the vascular work-up entirely.
| Risk | Why it matters in CRAO |
|---|---|
| Missed giant cell arteritis | Delayed steroid treatment risks bilateral blindness within days and systemic vascular complications — the single most time-critical diagnosis to exclude |
| Recurrent stroke or heart attack without work-up | The embolic source causing the CRAO remains untreated and can cause a subsequent, potentially disabling cerebral or cardiac event |
| Thrombolysis bleeding risk | IV tPA carries a real intracranial and systemic haemorrhage risk that, per the EAGLE trial, was not clearly offset by visual benefit |
| Anterior chamber paracentesis | An invasive bedside procedure with its own small risk of infection, hyphema or lens injury, for a benefit that remains unproven |
| Neovascular complications | Less common than after an ischemic central retinal vein occlusion, but iris and angle neovascularisation are documented after CRAO and warrant monitoring for months afterward |
| Permanent field loss despite guideline-concordant care | Even prompt, correct management does not reliably restore central vision once infarction has occurred — the retina's poor collateral supply is the fundamental limit, not a failure of treatment |
Section 07 — Where the Decision Actually Gets Made
The eye exam ends.
The stroke
work-up begins.
In a well-run pathway, the ophthalmologist's job is not just to diagnose CRAO on fundus exam — it is to trigger the same urgent referral a neurologist would trigger for a TIA, on the same day, before the patient leaves the building.
That work-up looks functionally identical to a TIA clinic pathway, run in parallel with the ophthalmic assessment rather than instead of it: same-day carotid duplex ultrasound, an electrocardiogram and often extended cardiac monitoring for paroxysmal atrial fibrillation, echocardiography where a cardioembolic source is suspected, same-day ESR and CRP with a low threshold for temporal artery biopsy in patients over 50, and a full lipid and vascular risk-factor review.
A patient in their late sixties wakes up with painless, complete loss of vision in one eye and is seen the same morning. Fundus exam shows retinal whitening and a cherry-red spot consistent with CRAO. No headache, no jaw pain, nothing pointing toward arteritis. What the eye exam cannot show is why the artery blocked — that question sends the patient for carotid duplex imaging the same day, which finds a high-grade stenosis on the side matching the affected eye.
The vision in that eye does not meaningfully recover; by the time of presentation, the ischemic window described in the animal-model data had already closed. But the carotid finding changes the rest of the patient's care — evaluation for endarterectomy or stenting, antiplatelet therapy, risk-factor management — precisely the intervention that reduces the risk of a subsequent, and potentially far more disabling, cerebral stroke. The eye did not save its own vision. It found the disease that could have taken far more.
Section 08 — FAQ
Frequently asked questions
about CRAO.
CRAO is a sudden blockage of the central retinal artery, the vessel that supplies blood to the inner layers of the retina. It typically causes sudden, painless, and often severe loss of vision in one eye, and is usually caused by an embolus — a fragment of clot or cholesterol plaque — travelling from the carotid arteries or the heart.
Functionally, yes. The retina is technically part of the central nervous system, and a CRAO is caused by the same kind of vascular blockage — usually an embolus — that causes an ischemic stroke in the brain. In 2021 the American Heart Association and American Stroke Association formally classified acute retinal ischemia as a stroke subtype and recommended the same urgent vascular work-up used for cerebral stroke or TIA, regardless of whether vision in the eye recovers.
It's the classic fundus exam finding in CRAO. The retina around the macula turns pale as the inner retinal layers infarct and swell, while the very centre of the macula — the fovea, which has almost no inner retinal tissue and sits over the still-intact choroidal blood supply — stays comparatively red by contrast. It's a sign of the pattern of damage, not evidence that central vision has been spared.
Sometimes, but it is unpredictable and often limited. Recovery depends heavily on how quickly blood flow is restored, whether a protective cilioretinal artery happens to spare part of the macula, and how complete the original blockage was. Animal-model data suggests the retina's tolerance for complete ischemia is on the order of 90 minutes to a few hours before damage becomes substantial, which is why CRAO is treated as a true time-critical emergency even though, honestly, no treatment reliably reverses established damage.
The eye exam confirms the diagnosis, but the more important work happens afterward: same-day carotid duplex ultrasound, an ECG and often extended heart-rhythm monitoring, blood tests including ESR and CRP to screen for giant cell arteritis, and a broader cardiovascular risk-factor review. The goal is finding the embolic or inflammatory source before it causes a second, potentially more disabling event — commonly a cerebral stroke.
Giant cell arteritis is an inflammatory disease of medium and large arteries that, in patients typically over 50, can cause an arteritic form of CRAO. It matters because it is treated completely differently from embolic CRAO — with urgent high-dose systemic corticosteroids, often started before a confirmatory temporal artery biopsy — and because an untreated arteritic CRAO carries a real risk of blinding the second eye within days if not recognised.
References & Evidence Base
Peer-reviewed
citations.
Continue Reading
Related guides
from Beyond Vision.
Start writing here...
Central Retinal Artery Occlusion (CRAO): Sudden Vision Loss & Eye Stroke Guide (2026 Guide)